Extrapyramidal reaction associated with ondansetron. 1993

X Garcia-del-Muro, and F Cardenal, and P Ferrer

UI MeSH Term Description Entries
D009303 Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX. Cancer of Nasopharynx,Nasopharyngeal Cancer,Cancer of the Nasopharynx,Nasopharynx Cancer,Nasopharynx Neoplasms,Neoplasms, Nasopharyngeal,Cancer, Nasopharyngeal,Cancer, Nasopharynx,Cancers, Nasopharyngeal,Cancers, Nasopharynx,Nasopharyngeal Cancers,Nasopharyngeal Neoplasm,Nasopharynx Cancers,Nasopharynx Neoplasm,Neoplasm, Nasopharyngeal,Neoplasm, Nasopharynx,Neoplasms, Nasopharynx
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001480 Basal Ganglia Diseases Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA. Extrapyramidal Disorders,Basal Ganglia Disorders,Lenticulostriate Disorders,Basal Ganglia Disease,Basal Ganglia Disorder,Extrapyramidal Disorder,Lenticulostriate Disorder
D014839 Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH. Emesis
D017294 Ondansetron A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties. 4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-,Zofran ODT,GR-38032F,GR38032F,Ondansetron Hydrochloride,Ondansetron Monohydrochloride,Ondansetron Monohydrochloride Dihydrate,Ondansetron, (+,-)-Isomer,Ondansetron, (R)-Isomer,Ondansetron, (S)-Isomer,SN-307,Zofran,Dihydrate, Ondansetron Monohydrochloride,GR 38032F,Hydrochloride, Ondansetron,Monohydrochloride Dihydrate, Ondansetron,Monohydrochloride, Ondansetron,ODT, Zofran,SN 307,SN307

Related Publications

X Garcia-del-Muro, and F Cardenal, and P Ferrer
March 1992, Cancer,
X Garcia-del-Muro, and F Cardenal, and P Ferrer
October 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
X Garcia-del-Muro, and F Cardenal, and P Ferrer
February 1994, The Annals of pharmacotherapy,
X Garcia-del-Muro, and F Cardenal, and P Ferrer
October 1998, British journal of anaesthesia,
X Garcia-del-Muro, and F Cardenal, and P Ferrer
February 1996, The Annals of pharmacotherapy,
X Garcia-del-Muro, and F Cardenal, and P Ferrer
January 1999, Anesthesiology,
X Garcia-del-Muro, and F Cardenal, and P Ferrer
January 2009, Movement disorders : official journal of the Movement Disorder Society,
X Garcia-del-Muro, and F Cardenal, and P Ferrer
May 1995, Oncology nursing forum,
X Garcia-del-Muro, and F Cardenal, and P Ferrer
March 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
X Garcia-del-Muro, and F Cardenal, and P Ferrer
March 1963, Virginia medical monthly,
Copied contents to your clipboard!